Abstract & case submission
Abstract & case submission is an important part of the virtual edition EHA-SWG Scientific Meeting on Immunotherapy for hematological disorders. As a participant, you will have the opportunity to submit an abstract or case for this meeting, and (if accepted) have the possibility to discuss it with the international faculty and your peers. Abstracts & cases can be submitted (or revised) until the deadline of October 16, 2020 (23:59 CEST).
Abstract submission has closed
A selection of abstracts will be eligible for acceptance during the meeting. The exact format in a virtual environment is currently being discussed and will be announced shortly. Certain is that accepted abstracts will be part of the program.
You can submit an abstract on one of the following topics:
- Leukemia-reactive T cells after allogeneic HCST,
- Treatment with innate immune cells (NK, gamma/deltaTcells, DC),
- TCR transgenic T cells,
- Checkpoint blockers,
- Other immunotherapies: Antibody, RNA and DNA based,
- Immune system and microbiome,
- Bispecific antibodies,
- Immunotherapy and laboratory testing,
- Innovative antibody formats, and
- Artificial intelligence and immunotherapy.
The abstracts will be reviewed and allocated by the Scientific Program Committee. Submitting authors will be informed about the allocation by October 23, 2020.
Please note that the submission of an abstract constitutes a formal commitment by the author to attend the meeting (if the abstract is accepted) and if required present the abstract as an oral presentation or poster presentation in the session and the time assigned by the Scientific Program Committee.
We therefore recommend that presenting authors of abstracts register for the meeting simultaneously with abstract submission. For more information about registration and to register, click here.
Should you have any questions, please contact email@example.com.